Evidence map›Paper›PMID 38413480›Full record

ReviewActa neurologica Belgica2024

A review of type 3 Gaucher disease: unique neurological manifestations and advances in treatment.

Wei Zhong, Dan Li, Yue Fei, Pan Hong

Abstract readReview
PubMed Publisher
In one paragraph

Review in Acta neurologica Belgica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Wei ZhongShaoxing University, Shaoxing, 312000, Zhejiang, China.
Dan LiDepartment of Hematology, Shaoxing People's Hospital, 568 Zhongxing North Road, Shaoxing, 312000, Zhejiang, China.
Yue FeiShaoxing University, Shaoxing, 312000, Zhejiang, China.
Pan HongDepartment of Hematology, Shaoxing People's Hospital, 568 Zhongxing North Road, Shaoxing, 312000, Zhejiang, China. hongpan168@163.com.ORCID http://orcid.org/0000-0002-0578-919X
Shaoxing People's Hospital · CNShaoxing University · CN

Funding

Medical Science and Technology Project of Zhejiang Province 2021KY1137Medical Science and Technology Project of Zhejiang Province 2023RC290
6 · The paper itself

Abstract

Gaucher disease (GD) is a rare lysosomal storage disease that is caused by mutations in the GBA gene. It is classified into three main phenotypes according to the patient's clinical presentation. Of these, chronic neuronopathic GD (GD3) is characterized by progressive neurological damage. Understanding the unique neurological manifestations of GD3 has important diagnostic and therapeutic implications. Our article summarizes the neurological symptoms specific to GD3 and related therapeutic advances, and it highlights the relevance of the gene to clinical symptoms, so as to provide a reference for the diagnosis and treatment of GD3.

Indexed as

Gaucher DiseaseEnzyme Replacement TherapyGlucosylceramidaseHumansNervous System DiseasesGlucosylceramidaseGBANeuropathy of type 1 Gaucher diseaseNeuropathy of type 3 Gaucher diseaseTreatmentType 3 Gaucher disease

Identifiers

PMID38413480
OpenAlexW4392235619

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.